FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer

Colorectal cancer patients with BRAF-mutant tumors have a more aggressive, rapidly progressing disease that is in critical need of novel therapeutic approaches. Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) patients receiving standard-of-care therapy is approximately tw...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lim, Bora, Scicchitano, Angelique, Beachler, Cheryl, Gusani, Niraj, Sarwani, Nabeel, Yang, Zhaohai, Staveley-O’Carroll, Kevin, Ashkenazi, Avi, Portera, Chia, El-Deiry, Wafik S
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2013
Matèries:
Bedside to Bench Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841210/
https://ncbi.nlm.nih.gov/pubmed/23792567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25310
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars